相关实验视频

Updated: May 25, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在现实世界中设置的先进固体瘤患者的瘤纤维细胞生长因子受体变化的预后影响

Levon Demirdjian¹, Spyros Triantos¹, Kristopher Standish¹

¹Janssen Research & Development, Spring House, Pennsylvania, USA.

Cancer medicine

|February 26, 2025

概括

实体纤维细胞生长因子受体基因 (FGFRalt) 改变不会影响晚期固体瘤的整体存活率. 这种现实世界分析发现,在接受标准护理的FGFRalt或不接受FGFRalt患者的结果中没有显著差异.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
癌症研究癌症研究

背景情况:

人体纤维细胞生长因子受体基因变异 (FGFRalt) 被认为是各种癌症的致癌驱动因素.
在固体瘤中FGFRalt的预后意义仍然不完全理解.
这项研究调查了FGFRalt对综合存活 (OS) 的影响,在一个多样化,现实世界的患者队列中,这些患者患有晚期固体瘤.

研究的目的:

评估FGFRalt对晚期固体瘤患者的整体生存期 (OS) 的预后影响.
为了比较FGFRalt患者和没有FGFRalt患者之间的OS,在瘤不可知,现实世界的环境中.
评估FGFRalt对患者接受标准护理治疗时预后的影响.

主要方法:

一个非识别的临床基因组数据库的回顾性,观察性,比较性队列分析.
纳入标准:晚期/转移性疾病,年龄≥18岁,对FGFRalt进行基因组测试,并开始一线全身治疗.
患有FGFRalt的患者与FGFR阴性 (FGFRneg) 患者3:1匹配,使用精确和Mahalanobis距离匹配;OS是主要终点,用Cox模型分析.

主要成果:

该队列包括30种瘤类型的1012名患者 (253名FGFRalt,759名FGFRneg).
在FGFRalt和FGFRneg组之间没有观察到FGFRalt和FGFRneg组之间的第一线治疗对现实世界OS的显著差异 (HR 0.97,p=0.78).
平均生存期为1.13年 (FGFRalt) 和1.01年 (FGFRneg).

结论:

FGFRalt似乎不会影响接受标准治疗的高级固体瘤患者的预后.
这种现实世界,匹配的队列分析表明,FGFRalt在这个患者群体中不是一个显著的预后因素.
进一步的研究可能会探索与FGFRalt状态相关的特定亚型或向疗法.

关键词:

赫达菲提尼布 (herdafitinib) 是一种药物.纤维细胞生长因子抑制剂现实世界的证据.瘤不可知论者是一个瘤不可知论者.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...